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tional approach for recanalization of long below-the-knee (BTK)
chronic total occlusions (CTOs) in patients with critical limb ischemia
(CLI). However, whether primary implantation of self-expanding
nitinol stent in BTK lesions after SIA can improve clinical outcomes is
not known.
METHODS In a multicenter, prospective registry study, we enrolled
90 CLI patients with long BTK lesions (> 5cm), who were treated with
SIA from Oct 2011 to Feb 2015. In all patients, primary stenting with
self-expanding nitinol stent (Maris Deep, Medtronic) was performed
in tibial arteries (anterior tibial artery, n¼65; posterior tibial artery,
n¼25) after SIA. Mean target lesion length and stent length was 20.6 
8.8 cm and 6.1  1.9 cm, respectively. The primary endpoint was
adverse limb events (ALE), a composite of unexpected amputation,
and repeated percutaneous transmembrane angioplasty (PTA) and the
secondary endpoint were limb salvage, all-cause death, major or mi-
nor amputation during the follow up (median 12 months, interquartile
range 6-12 months).
RESULTS Mean age was 70  10 years old and there were 82% men,
76% diabetes mellitus, 13% end stage renal disease patients. Technical
success rate of subintimal angioplasty was 98.9% and procedure-
related complication rate was 2.2%. During the follow up, 15 ALEs
(16.7%, 14 repeated PTA, 1 unexpected minor amputation) occurred.
Limb salvage rate was 100%. In addition, there were 5 planned minor
amputations (6.7%), no major amputation, 2 cardiovascular mortal-
ities (2.2%) and 7 non-cardiovascular mortalities (11.7%). There was no
signiﬁcant difference in age, gender, clinical variables and medica-
tions except for statin (82.7% vs. 53.3% for ALE, p¼0.036) between
ALE and non-ALE group. In a Cox hazard regression analysis, statin
use was associated with decreased ALE after adjusting other risk
factors (hazard ratio 0.315, 95% conﬁdence interval 0.114 – 0.874,
p¼0.026).
CONCLUSIONS Primary stenting with self-expanding nitinol stent
after SIA in BTK CTOs was safe. Limb salvage rate was excellent. The
event rate for repeat interventions appears to be favorable. Statin use
may be beneﬁcial for reducing ALE in CLI patients with long BTK
lesions.
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BACKGROUND An atherectomy is a minimally invasive catheter-
based procedure to remove plaque from arteries and is particularly
useful in cases where the plaque is very hard due to calciﬁcation.
There is lack of data on the impact of hospital volume on outcomes
following percutaneous peripheral atherectomy of other non-coro-
nary vessels. An aim of study is to see effect of hospital volume on the
length of stay (LOS) and cost of hospitalization of percutaneous pe-
ripheral atherectomy.
METHODS We queried the Healthcare Cost and Utilization Project’s
National Inpatient Sample (NIS) of year of 2012. We identiﬁed pe-
ripheral vascular disease of lower limbs through validated ICD-9 codes
for acute and chronic limb ischemia and atherosclerosis of graft for
age more than 18 years. We sought for only peripheral atherectomy
with using ICD 9 procedural code 17.56. Annual hospital volume was
calculated using unique identiﬁcation numbers and then divided into
tertiles for analysis. Cost to charge ratio ﬁles were merged with NIS to
calculate cost of care. Cost was adjusted for inﬂation in reference to
2012.
RESULTS We identiﬁed a total of 4,203 procedures (weighted n ¼
21,015) with mean age 69.53 years, 56% male and 61% were whites.
Results shown the mean Deyo’s Modiﬁed Charlson score was 2.2,
Hypertension (79%), Diabetes (54%), Congestive heart failure (18%)
and 10% were obese. The average LOS was 6.12  0.11 days and cost of
care was $27,759  339. The highest tertile was showing both shorter
LOS (4.86  0.18 vs 6.79  0.2 days, p<0.0001) and lowerhospitalization cost ($23,062  496 vs $30,794  634, p<0.0001) than
lowest tertile (Figure).
CONCLUSIONS In our study, higher hospital volume was signiﬁcantly
predictive of reduced length of stay by approximately two days and
25% reduction in cost of hospitalization following percutaneous pe-
ripheral atherectomy in the United States.
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BACKGROUND Stent graft placement for femoro-popliteal arterial
obstructive disease is an FDA approved indication for the Gore Via-
bahn (WL Gore, Flagstaff, AZ, USA) stent, for both denovo and instent
restenosis (ISRS) lesions. To date there is little data on Viabahn stent
graft outcomes in patients with De novo and ISRS arterial disease.
METHODS Between 2007 and 2014 we identiﬁed 734 patients under-
went 1573 endovascular interventions in our institution for infra-
inguinal revascularization. Among these, 59 patients had 163 Viabahn
stents placed. Of these, 30 patients had 98 stents placed for ISRS and
29 patients had 65 stents placed for Denovo lesions.
RESULTS The patients in the ISRS group were more likely to have
hypertension, hyperlipidemia, coronary artery disease, history of
prior PCI and chronic kidney disease compared to the patients in the
De novo group. Stents were placed principally for femoro-popliteal
lesions, with mean length of 20 12.5 cm (21.811.5, ISRS Vs 18.213.4,
De novo; p¼0.09). Both groups had low primary patency rates during
one year follow up (51% Vs 49%, OR¼1 (0.5-2.2). Target lesion revas-
cularization(TLR) (58% Vs 25%, p<0.0001, OR¼4.2,CI¼2.1-8.5), cu-
mulative blockage (deﬁned as ISRS and thrombosis) (59% Vs 43%,
p¼0.04, OR¼2,CI¼1-3.6), and surgical revascularization (21% Vs 5%,
OR¼5.6,CI¼1.6 -19) occurred more frequently in the ISRS group than in
the De novo group. Amputation rate (18% Vs 23%, OR 0.7,CI¼0.3-1.8),
Restenosis (47% Vs 35%, OR 1.6,CI¼0.7-3.2) were not statistically
different between the two groups. Mean duration of follow-up was
15.1 13.9 months.
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(N[ 98)Denovo Group
(N[ 65) P (<0.05) Odds Ratio (CI)Primary patency
(Primary Endpoint)41/81 (51%) 20/41 (49%) 0.84 1 (0.5-2.2)Secondary Endpoint 66/98 (67%) 37/65 (57%) 0.17 1.5 (0.8-2.9)Cumulative blockage
(ISRSþ Re-
occlusion)58/98 (59%) 28/65 (43%) 0.04 1.96 (1-3.6)Restenosis 35/98 (47%) 20/65 (35%) 0.09 1.6 (0.7-3.2)Target Lesion
Revascularization57/98 (58%) 16/65 (25%) <0.0001 4.2 (2.1-8.5)TLR (Percutaneous
Intervention)51/98 (52%) 14/65 (22%) <0.0001 3.9 (1.9-8)TLR (Surgical
revascularization)21/98 (21%) 3/65 (5%) 0.003 5.6 (1.6-19)Amputation 18/98 (18%) 15/65 (23%) 0.46 0.7 (0.3-1.6)Primary Endpoint: Primary patency at 12 month of follow-up by either angiogram or Doppler scan
Secondary Endpoint: Amputation, Cumulative blockage ( ISRS þThrombotic re-occlusion), TLR (Percuta-
neous intervention and surgical revascularization)CONCLUSIONS Stent graft treatment using the Gore Viabahn for De
novo and ISRS in femoro-popliteal arterial obstructive disease have
high restenosis and failure rates, of both stent patency and limb
outcomes, which is consistent with existed literature. Failure of stent
grafts, used to treat ISRS associated with higher rates of TLR, occlu-
sion requiring bypass, compared to De novo lesions.
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North Texas Health Care System, Dallas, TX, Dallas, TXBACKGROUND Despite an exponential rise in lower extremity pe-
ripheral artery interventional (PAI) procedures in patients with
symptomatic peripheral artery disease (PAD) over the last decade,
adherence to guideline-based medical therapy (GMT) post-revascu-
larization has not been well described.
METHODS We analyzed PAIs registered in the Excellence in Peripheral
Artery Disease (XLPAD) registry (NCT01904851) from 13 U.S. centers
between 2005 and 2013 and evaluated adherence to GMT which is
comprised antiplatelet therapy (APT), lipid-lowering therapy (LLT) and
renin-angiotensin pathway inhibitors (RAI) with angiotensin receptor
blockers (ARB) and angiotensin converting enzyme inhibitors (ACEI).
RESULTS Analysis of 1532 PAI in the study periods (n¼55 in 2005-2007;
n¼314 in 2008-2010 and n¼1,163 in 2011-2013) demonstrates an exponen-
tial rise in PAIs, consistentwith national U.S. trends. Nevertheless, this rise
in PAI was not accompanied with an equally robust adherence to GMT.
Excluding, the limited number of patients enrolled from 2005-2007, the
period between 2008 and 2013, demonstrates suboptimal adherence to
GMTacross all therapygroups (Figure 1). APTprescriptions fell from90%to
77%, between 2008-2010 and 2011-2013 (p<0.001), and dual-APT
prescriptions remained consistently low during the periods (53% vs.
48%). Consistent with the overall trend of dropping adherence to GMT
between the periods 2008-2010 and 2011-2013 (55% vs. 42%; p<0.001),
individual prescription of LLT and RAI were also signiﬁcantly lower (83%
vs. 66% for LLT; p<0.001 and 62% vs. 49% for RAI; p<0.001),
respectively. During the same periods, all-cause death and non-fatal
myocardial infarction (MI) rates were 7% and 5%, and need for repeat
endovascular revascularization (RR) rates remain high at 28% and 19%
for the periods 2008-2010 and 2011-2013, respectively.
CONCLUSIONS Given the high death, MI and RR rates in patients un-
dergoing PAI, and suboptimal adherence to GMT, there is an urgent need
for national performance standards to monitor GMT in patients with PAD.CATEGORIES ENDOVASCULAR: Peripheral Vascular Disease and In-
tervention
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BACKGROUND A number of small studies have suggested that out-
comes following endovascular therapy (ENDO) are comparable to
those following surgical revascularization (SURG) for patients pre-
senting with acute limb ischemia (ALI). We sought to compare mor-
tality, limb amputation and recurrent ischemia across both strategies.
METHODS MEDLINE, EMBASE and CENTRAL electronic databases
were comprehensively searched from January 1990 through May 2015
to identify studies of ENDO versus SURG for ALI. Two independent
reviewers selected studies and extracted the data. Random-effects
meta-analysis was used to pool results across studies. Heterogeneity of
treatment effect among trials was assessed using the I2 statistics. The
primary endpoints were mortality and limb amputation at 1, 6 and 12
months. Secondary endpoint was recurrent ischemia at one year.
